Identity
- Security key
- 17891
- Ticker
- LABT
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2026-04-23
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- LABT
Detail
Enriched 2026-08-14 20:47
- Market cap
- $4,131,550.52
- Shares outstanding (class)
- 2,369,688
- Shares outstanding (weighted)
- 1,750,657
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- —
- Location
- UNIVERSITY PARK, FL
- Homepage
- https://lakewoodamedex.com
- Description
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
Market cap and share counts drift.